BRAF (42.1 % of patient samples, 16 of 38), MECOM (36.8 %, 14 of 38), NRAS (36.8 %, 14 of 38), TP53 (31.6 %, 12 of 38), MLL2 (29.0 %, 11 of 38), as well as CDKN2A (29.0 %, 11 of 38) were among the most commonly mutated genes among the patient melanoma samples. This evidence concerns the gene KMT2D and melanoma.